OverviewSuggest Edit

CareDx is a global transplant diagnostics company with product offerings along the pre- and post-transplant continuum. The Company focuses on discovery, development, and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant patients. CareDx's first commercialized post-transplant testing solution, the AlloMap heart transplant molecular test, or AlloMap, is a gene expression testing service that helps clinicians monitor and identify heart transplant recipients with stable graft function who have a low probability of moderate-to-severe acute cellular rejection.

The Company believes the use of AlloMap, in conjunction with other clinical indicators, can help healthcare providers and their patients better manage long-term care following a heart transplant. In particular, AlloMap can improve patient care by helping healthcare providers avoid the use of unnecessary, invasive surveillance biopsies and determine the appropriate dosage levels of immunosuppressants. The Company is also pursuing the development of additional products for transplant monitoring using a variety of technologies, including AlloSure, its proprietary next-generation sequencing-based test to detect donor-derived cell-free DNA, or dd-cfDNA, after transplantation.

TypePublic
Founded2000
HQBrisbane, US
Websitecaredxinc.com

Latest Updates

Employees (est.) (Dec 2018)227(+35%)
Revenue (FY, 2018)$76.6 M(+59%)
Share Price (Nov 2019)$19.7 (+3%)

Key People/Management at CareDx

Michael D. Goldberg

Michael D. Goldberg

Chairman of the Board, CareDx, Inc
Amy Abernethy

Amy Abernethy

Chief Medical Officer, Chief Scientific Officer and Senior Vice President, Oncology
George W. Bickerstaff

George W. Bickerstaff

Managing Director, MM Dillon & Co
Fred E. Cohen

Fred E. Cohen

Managing Director, TPG Ventures
William Hagstrom

William Hagstrom

CEO, Octave Bioscience
Peter Maag

Peter Maag

Chief Executive Officer and President, CareDx, Inc
Show more

CareDx Office Locations

CareDx has an office in Brisbane
Brisbane, US (HQ)
3260 Bayshore Blvd
Show all (1)

CareDx Financials and Metrics

CareDx Revenue

CareDx's revenue was reported to be $76.57 m in FY, 2018
USD

Revenue (Q3, 2019)

28.2m

Market capitalization (15-Nov-2019)

837.3m

Closing stock price (15-Nov-2019)

19.7

Cash (30-Sep-2019)

40.9m
CareDx's current market capitalization is $837.3 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

27.3m28.1m40.6m48.3m76.6m

Revenue growth, %

3%44%

Cost of goods sold

8.5m10.3m10.2m9.0m

Gross profit

18.8m17.9m30.4m39.3m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

6.8m6.7m7.2m7.1m7.2m6.6m10.7m12.5m11.6m12.0m12.2m14.1m17.8m21.2m26.0m31.5m28.2m

Cost of goods sold

2.4m1.8m2.7m2.5m2.6m2.8m3.1m3.4m2.3m2.2m2.1m2.3m11.5m

Gross profit

4.4m4.9m4.5m4.6m4.6m3.8m7.7m9.1m9.3m9.9m10.1m11.8m19.9m

Gross profit Margin, %

65%73%62%65%64%58%72%73%80%82%83%84%63%
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

36.4m29.9m17.3m16.9m64.6m

Accounts Receivable

2.7m2.4m2.8m3.0m9.8m

Prepaid Expenses

1.4m1.8m

Inventories

686.0k766.0k5.5m5.5m4.9m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

781.0k(13.7m)(39.8m)(55.6m)(46.8m)

Depreciation and Amortization

512.0k796.0k2.9m3.8m4.2m

Inventories

(168.0k)(80.0k)492.0k1.0m363.0k

Accounts Payable

510.0k489.0k(620.0k)292.0k(168.0k)
USDY, 2019

Financial Leverage

1.5 x
Show all financial metrics

CareDx Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
XynManagementAugust 29, 2019

CareDx Online and Social Media Presence

Embed Graph

CareDx News and Updates

Eurofins Viracor, Inc. Responds to Patent Infringement Lawsuit By CareDx

LEE'S SUMMIT, Mo., Sept. 26, 2019 /PRNewswire/ -- Eurofins Viracor, Inc. ("Viracor") became aware today that CareDx has filed suit in the United States District Court for District of Delaware, alleging infringement of U.S. Patent No. 8,703,652 by three of Viracor's tests: Viracor TRAC™...

CareDx Files Patent Infringement Lawsuit Against Eurofins Viracor

CareDx protects transplantation innovation by enforcing patent protection CareDx protects transplantation innovation by enforcing patent protection

CareDx Acquires XynManagement

Acquisition solidifies transplant leadership with transplant center quality management and patient waitlist management tools Acquisition solidifies transplant leadership with transplant center quality management and patient waitlist management tools

CAREDX INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In CareDx, Inc. To Contact The Firm

NEW YORK, July 24, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against CareDx, Inc. ("CareDx" or the "Company") (NASDAQ:CDNA). If you invested in CareDx stock or options and would like to discuss your legal rights,...

CDNA INVESTIGATION ALERT: Bernstein Liebhard LLP Announces Investigation of CareDx Inc.-- CDNA

NEW YORK, July 17, 2019 /PRNewswire/ -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of CareDx Inc. ("CareDx" or the "Company") (NASDAQ: CDNA) resulting from allegations that CareDx...

CDNA INVESTIGATION ALERT: Hagens Berman Alerts CareDx (CDNA) Investors to Investigation of Possible Disclosure Violations

SAN FRANCISCO, July 16, 2019 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP notifies investors in CareDx, Inc. (NASDAQ: CDNA) of the firm's investigation of possible disclosure violations. The investigation concerns matters raised on July 16, 2019 by Kerrisdale Capital's report...
Show more

CareDx Blogs

Grace E. Colón

Grace E. Colón Reynally.Merca… Tue, 11/12/2019 - 13:42 Grace E. Colón, PhD President & CEO - Incarda Therapeutics, Inc Grace E. Colón, has served as President, Chief Executive Officer and Director of InCarda Therapeutics, Inc., a clinical stage company dev…

Chris Cournoyer

Chris Cournoyer Reynally.Merca… Tue, 11/12/2019 - 13:36 Chris Cournoyer Chairperson and Chief Executive Officer for N-of-One Chris Cournoyer is presently a strategic advisor to QIAGEN and prior to that served as the Chairperson and Chief Executive Officer for N-o…

CareDx at ASN Kidney Week

CareDx at ASN Kidney Week Content Import Wed, 11/06/2019 - 07:01 CareDx at ASN Kidney Week Nov 06, 2019 This release is a backfill from a News Wire General AlloSure highlighted at the American Society of Nephrology Conference BRISBAN…

CareDx Advances Patient Care with AlloSure 3.0

CareDx Advances Patient Care with AlloSure 3.0 Content Import Mon, 11/04/2019 - 07:01 CareDx Advances Patient Care with AlloSure 3.0 Nov 04, 2019 This release is a backfill from a News Wire General CareDx drives continued transplant …

CareDx Reports Third Quarter 2019 Results

AlloSure momentum drives 60% third quarter revenue growth BRISBANE, Calif. , Oct. 31, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (NASDAQ: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare

CareDx to Announce Third Quarter 2019 Financial Results on October 31st, 2019

BRISBANE, Calif. , Oct. 17, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced
Show more

CareDx Frequently Asked Questions

  • When was CareDx founded?

    CareDx was founded in 2000.

  • Who are CareDx key executives?

    CareDx's key executives are Michael D. Goldberg, Amy Abernethy and George W. Bickerstaff.

  • How many employees does CareDx have?

    CareDx has 227 employees.

  • What is CareDx revenue?

    Latest CareDx annual revenue is $76.6 m.

  • What is CareDx revenue per employee?

    Latest CareDx revenue per employee is $337.3 k.

  • Who are CareDx competitors?

    Competitors of CareDx include Kewaunee, Prelude Fertility and Geratherm.

  • Where is CareDx headquarters?

    CareDx headquarters is located at 3260 Bayshore Blvd, Brisbane.

  • Where are CareDx offices?

    CareDx has an office in Brisbane.

  • How many offices does CareDx have?

    CareDx has 1 office.